slides · global inventory
27 Cost Of Inaction
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 31,900
Current window 18,211-18,240
Pages 1,064
Rows per page 30
Loop
18,211-18,240 of 31,900
07
Includes a highlight box around the 2022 column. Data is in Euro MM.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
08
The table compares 2022 and 2021 June YTD figures with percentage changes.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
05
The table uses a waterfall-style logic to explain the variance between previous and updated outlooks.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations Beat · What Could BeLoop · Cost Of Inaction1 hit
04
The slide outlines a financial challenge (funding gap) and specific operational strategies to address it.SkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide details a specific bond indenture modification strategy to improve credit metrics.SkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
SkyHarbour | Investor Presentation Deck | 8 slidesSkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
05
The slide uses a visual comparison framework to position TRuC-T cells as a superior technological evolution.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
The slide uses a 2x2 layout to present four distinct experimental results supporting the superiority of TRuC technology.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
07
The slide uses a comparative structure to frame gavo-cel as a superior therapeutic option compared to historical anti-mesothelin CAR-T approaches.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
05
The slide uses a central hub-and-spoke diagram to show the mast cell as the central point of failure/intervention.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
06
The data highlights the mechanism of action of KIT inhibition (inactivation and depletion) supported by Phase 1b interim results.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide presents a summary of preclinical efficacy and safety data alongside a table demonstrating high selectivity against other kinases.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide uses a staircase diagram to represent dose escalation and a crossover diagram for the food effect study.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
09
The chart displays multiple dose cohorts (200mg QD, 200mg BID, 400mg BID, 500mg QD FED) with error bars representing standard deviation.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
10
The table displays counts and percentages of subjects experiencing specific adverse events. 'MAD' stands for Multiple Ascending Dose.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
11
The chart tracks neutrophil levels across multiple cohorts (placebo, 200mg QD, 200mg Q12H, 400mg Q12H, 500mg QD FED) from Day 1 to Day 70/EOS, with a vertical line marking the end of treatment at Day 14.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
12
The slide includes a disclaimer that cross-study comparisons are unreliable due to differences in study design.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
13
Includes two line charts: one normalized to baseline and one showing absolute values.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
14
The schematic illustrates a dose escalation study with three cohorts of 10 patients each, separated by safety review committee (SRC) checkpoints.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
15
The chart shows a pharmacokinetic (PK) profile comparing two formulations of THB001.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
16
The slide uses clinical data to justify a new indication for a drug candidate by highlighting the role of mast cells in asthma pathophysiology.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
17
The slide outlines a randomized, placebo-controlled trial structure with specific allergen challenge points.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
18
The slide uses a timeline diagram to show clinical phases and key events (trial initiation, regulatory submission, data readout) from 2H'22 to 2H'24.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
19
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
20
Includes a patient quote and clinical imagery to emphasize the severity of the condition.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
21
Includes medical imagery of lungs and mast cells.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
25
The chart illustrates the shift in profitability dynamics over the second quarter of 2022.Vulcan Materials | Investor Day Presentation Deck | 91 slides · Vulcan Materials Company
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
26
Vulcan Materials | Investor Day Presentation Deck | 91 slidesVulcan Materials | Investor Day Presentation Deck | 91 slides · Vulcan Materials Company
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
27
Vulcan Materials | Investor Day Presentation Deck | 91 slidesVulcan Materials | Investor Day Presentation Deck | 91 slides · Vulcan Materials Company
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
28
The slide uses a simple horizontal block layout to categorize ESG priorities.Vulcan Materials | Investor Day Presentation Deck | 91 slides · Vulcan Materials Company
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit